Lantheus

#NEWS: Lantheus and GE HealthCare today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture and commercialize Lantheus’ leading PSMA PET imaging agent in Japan for #prostatecancer diagnostics and companion diagnostic use.     GE HealthCare will draw on its extensive manufacturing network and R&D expertise following its acquisition in March 2025 of Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan.    Read the full release: https://lnkd.in/e7EWKBmW     #LeadingRadiopharma 

Come visit us at #ASTRO25! Don’t miss this panel discussion—a case-based presentation with Steven Finkelstein MD FACRO & David Albala, MD. Learn how #Lantheus is advancing #radiopharmaceutical innovation.     We look forward to engaging with the #oncology community and contributing to the important dialogue on how to drive better outcomes in oncology.    View the program here: https://bit.ly/3UvWxes  

Here at #Lantheus, everything is falling into place, as we’re welcoming new colleagues and building momentum towards the future. 🍁🍂 This fall, we’re embracing exciting new chapters and bold ambitions. If you're passionate about radiopharmaceuticals and driven by patient-focused innovation, now’s the perfect time to join us as we #FindFightFollow disease to deliver better patient outcomes. Explore our open roles and take the next step in your journey this fall: https://bit.ly/LNTHCareers #FindFightFollow #LantheusIsHiring

On #WorldAlzheimersDay, we stand alongside our global colleagues Life Molecular Imaging and the broader Alzheimer’s community in raising awareness for one of the most pressing health challenges of our time. #AlzheimersDisease affects millions, placing an immense strain on patients, caregivers and the larger healthcare system. At #Lantheus, we are dedicated to making a difference.  As the leading radiopharmaceutical-focused company, #Lantheus is furthering our impact in neurodegenerative diseases, like #AD, advancing next-generation radiodiagnostic solutions that may help physicians detect disease earlier and deliver more informed decisions.  This work is driven by a single unified Purpose – to #FindFightFollow disease to deliver better patient outcomes for those who need it most.    Learn how we continue to advance the future of neurology: https://bit.ly/4lG88Cz

Tomorrow, our friend Eric will take on Mount Kilimanjaro as part of the inaugural #ZeroPeaksChallenge sponsored by ZERO Prostate Cancer. His journey is a powerful reminder that together, we can reach new heights in improving outcomes for this disease.     Hear more from Eric about what this challenge means to him and why he’s determined to make a difference.

We painted across the globe 🌎 today! Teams from Massachusetts, Germany and New Jersey came together as #OneLantheus to spend the day painting murals at #PaintFest - the Foundation for Hospital Art’s (FFHA) initiative to bring comfort and hope through art to people in healthcare facilities around the world. Thank you to everyone for bringing your creativity and collaboration to this event as we worked together to #FindFightFollow disease to deliver better patient outcomes. 🎨

The #BostonHeartWalk is next month, and #TeamLantheus is getting ready to step out in support of the American Heart Association. We’re proud to walk as #OneLantheus for those impacted by heart disease and stroke, and to help build a healthier future for all. Mark your calendar and get ready to join us. Every step we take moves us closer to stronger hearts and longer lives. Whether you're walking alongside us or cheering us on from afar, thank you for making a difference.    Learn more: 2025 Boston Heart Walk: https://lnkd.in/eanFqNKK

#TeamLantheus enjoyed connecting with experts in #cardiology at #ASE2025! We're excited to advance cardiac imaging solutions and look forward to continuing to #FindFightFollow for patients with #CVD.   

At Lantheus, our commitment to #GoFurther for patients begins with safety.    Patient safety is foundational to every solution we bring to life, from precision diagnostics to targeted radiotherapeutics. We hold ourselves to the highest standards of integrity and care on behalf of our providers, partners and patients.    On #WorldPatientSafetyDay, we proudly stand with the global healthcare community to champion a shared commitment: advancing a safer, stronger and more effective healthcare system for all. 

This #NationalHispanicHeritageMonth, Lantheus honors the strength of Hispanic and Latinx communities—and shines a light on a critical unmet need when it comes to their health.    #Prostatecancer is the most commonly diagnosed cancer among Latin men, yet they are significantly less likely to receive timely, definitive treatment. At #Lantheus, we’re committed to advancing radiodiagnostic innovations to support early and accurate detection.